Abstract:Objective To study the effect of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in diabetic difficult-to-heal skin ulcers. Methods Seventy cases of diabetic skin ulcers with difficult-to-heal ulcers admitted to the Center for Disease Control and Prevention of Nanping City, Fujian Province, from January 2021 to March 2022 were included, and grouped by randomized table method, the control group was treated with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) (a total of 35 cases), the research group was treated with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor (a total of 35 cases) The results of the study group were compared with the treatment effects of the two groups. Results The fasting blood glucose, 2 h postprandial blood glucose level and ulcerated area were lower in the study group than in the control group; compared with the control group, the total effective rate of the treatment was higher in the study group, and the time of muscle growth, time of expectoration of putrefaction, time of healing and the number of dressing changes were lower, and the difference was statistically significant (P<0.05). Conclusion The use of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in the treatment of diabetic patients with difficult-to-heal skin ulcers can reduce the patient's blood glucose level and promote ulcer healing.
Liu GX. Efficacy analysis of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in the treatment of diabetic skin ulcers that are difficult to heal[J]. Diabetes Mellitus New World, 2023, 26 (07): 72-75.